Add this topic to your myFT Digest for news straight to your inbox
Hit film about smuggling of generic drugs adds to pressure on multinationals
Christophe Weber ‘very comfortable’ with durability of lucrative haemophilia franchise
Swiss group seeks new growth areas to offset patent expiries on blockbuster drugs
Foundation Medicine acquisition a good fit with the Swiss group’s cancer care strategy
Clinical setbacks in cancer research are likely to be punished
Scientists are seeking combination drugs that would make for more effective treatments
Chief executive urges ‘realistic’ expectations amid threat of copycat biologic drugs
Swiss group’s success with combination therapy to tackle cancer weighs on rivals
Pharma group marks shift from empire-building to focus on science with CEO appointment
Roche and Novartis could serve as models for UK drugmakers after Brexit
Medicines from Roche, GSK and Novartis now eligible for government insurance scheme
Large trial shows only marginal benefit from taking cocktail of Herceptin and Perjeta
The challenge is to keep treatments affordable but still encourage innovation
Promising results for Perjeta used in bolster Swiss group against copycat threat
Comments come as Swiss drugmaker reports 4% increase in group sales
International Edition